Table 1.

Summary of Adverse Events Through Week 48

AE, na(%)Placebo n = 90DEUC 3 mg BID n = 91DEUC 6 mg BID n = 93DEUC 12 mg QD n = 89
AE79 (87.8)85 (93.4)81 (87.1)75 (84.3)
SAE11 (12.2)7 (7.7)8 (8.6)7 (7.9)
AEs leading to treatment discontinuation3 (3.3)8 (8.8)6 (6.5)11 (12.4)
Skin-related AEsb12 (13.3)15 (16.5)32 (34.4)30 (33.7)
Overall infections/infestations48 (53.3)60 (65.9)60 (64.5)45 (50.6)
Serious infections/infestations1 (1.1)1 (1.1)2 (2.2)1 (1.1)
Infections of interest
 Tuberculosis0000
 Herpes zosterc4 (4.4)3 (3.3)3 (3.2)2 (2.2)
 Influenza1 (1.1)3 (3.3)1 (1.1)3 (3.4)
 COVID-193 (3.3)3 (3.3)5 (5.4)3 (3.4)
Malignancy events1 (1.1)d1 (1.1)e01 (1.1)f
MACE0000
Thrombotic events0000
  • an is the number of patients who experienced an event. bIncludes (≤8.6% in any arm) acne, rash, dermatitis acneiform, pruritus, skin lesion, urticaria. cIncludes herpes zoster, herpes ophthalmic, genital herpes zoster. dBasal cell carcinoma. eBreast carcinoma. fVaginal squamous cell carcinoma.

  • AE, adverse event; COVID-19, coronavirus disease 2019; DEUC, deucravacitinib; MACE, major adverse cardiac events; SAE, serious adverse event.